Navigation Links
Arpida Announces Agenda Items for Shareholders Meeting
Date:4/15/2008

stant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
2. Arpida Announces Full Year 2007 Financial Results
3. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida-Supported CME Symposium Available Online
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. Arpida Interim Results for six Months to 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Consistent,Electronic Health Record for All Citizens Using City ... GREAT RIVER, N.Y., Oct. 16 Netsmart Technologies, ... for health and,human services organizations, today announced it ... contract by the City and County of San,Francisco, ...
... access to advanced gene-sequencing,technologies and gives new hope ... 16 Swedish Neuroscience,Institute (SNI) today announced that ... Hill Campus, the Center for Advanced Brain Tumor,Treatment ... patients diagnosed,with both benign and malignant brain tumors. ...
... Phase 3 CAPACITY Program - ... rate in CAPACITY -, BRISBANE, Calif., Oct. 16 ... 16, 2008, the Japanese,Ministry of Health, Labor and Welfare (MHLW) ... Ltd. to market pirfenidone,for the treatment of patients with idiopathic ...
Cached Biology Technology:Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System 2Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System 3Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 2Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 3Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 4InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 2InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 3InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 4
(Date:9/1/2014)... Mass-- Conventional wisdom has long held that corals ... coral reefs are passive organisms that rely ... such as nutrients and oxygen. But now scientists ... (WIS) in Israel have found that they are ... water into turbulent patterns that greatly enhance their ...
(Date:9/1/2014)... About 50 years ago, electron microscopy revealed the presence ... around and disappear. But scientists still don,t know what ... of proteins are believed to be crucial to the ... new approach to disease treatment., In the Journal ... call to investigators from various backgrounds, from biophysics to ...
(Date:8/31/2014)... A new blood test provides a fast and ... new proof-of-concept study shows. The newly developed test ... to detect active tuberculosis in children. The test ... tests in combination with speed of a blood ... for the diagnosis of tuberculosis in children, particularly ...
Breaking Biology News(10 mins):Nature's tiny engineers 2Nature's tiny engineers 3Scientists call for investigation of mysterious cloud-like collections in cells 2New tuberculosis blood test in children is reliable and highly specific 2
... German . , EASY-HIT** is a new cell-based ... This system was developed under the leadership of Professor Ruth ... the system are cultured human cells that allow HIV to ... producing a red fluorescent protein. The EASY-HIT technology can be ...
... Colo. (December 1, 2010) A major new study ... fetus to those smells and flavors, but physically changes the ... the future. "This highlights the importance of eating ... and nursing," said Josephine Todrank, PhD, who conducted the two-year ...
... from the UC Davis Health System have found that ... are significantly reduced in patients in the Sacramento area ... that affects about one in three U.S. adults and ... The study is the first to examine vitamin-D ...
Cached Biology News:A powerful new technology to identify HIV inhibitors 2Study shows pregnant mother's diet impacts infant's sense of smell 2Study finds low vitamin-d levels in northern California residents with metabolic syndrome 2Study finds low vitamin-d levels in northern California residents with metabolic syndrome 3Study finds low vitamin-d levels in northern California residents with metabolic syndrome 4
... cells for DNA isolation. Designed ... (includes 96 well plate adapters from ... the entire plate length (max capacity ... be used for soil, microorganisms, animal ...
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Biology Products: